Effective treatment for prevention of post-operative adhesion after strabismus surgery in experimental rabbit model: 0.5 % tranilast ophthalmic solution by Sang Uk Choi et al.
RESEARCH ARTICLE Open Access
Effective treatment for prevention of
post-operative adhesion after strabismus
surgery in experimental rabbit model:
0.5 % tranilast ophthalmic solution
Sang Uk Choi, Kyoung Woo Kim and Nam Ju Moon*
Abstract
Background: Postoperative adhesion is one of the major complications of strabismus surgery and result in motility
dysfunction that brings unpredictable surgical outcomes. However, there was no definitely accepted treatment
method to prevent postoperative adhesion.
Methods: A prospective, randomized, controlled experimental animal study was performed. Both eyes of each
of 14 New Zealand White rabbits underwent superior rectus muscle recession. After the surgical procedure, the
subjects were divided randomly into two groups; 0.5 % tranilast ophthalmic solutions and fluoroquinolone
antibiotic eye drops were administered to the group tranilast (N = 14), while the group control (N = 14) received
fluoroquinolone eye drops only. Five weeks after surgery, we evaluated gross adhesions with a numeric score
(0 to 4). In addition, histopathologic examination with hematoxylin & eosin staining, Masson’s-trichrome staining,
and anti-transforming growth factor beta 1 (TGF-β1) immuno-histochemical staining were done.
Results: The group tranilast showed significantly less gross adhesion and inflammation than the group control
(P = 0.01 and P < 0.001, respectively). Masson’s-trichrome staining revealed that post-operative collagen deposition
was more prominent in the group control than the group tranilast (P < 0.001). Moreover, remarkable TGF-β1
expression was observed in areas with excessive collagen deposition.
Conclusions: Instillation of 0.5 % tranilast ophthalmic solution is a simple and effective method for preventing
post-operative adhesion after strabismus surgery.
Keywords: Tranilast, Strabismus surgery, Adhesion
Background
Postoperative adhesion is one of the major com-
plications of strabismus surgery and result in motility
dysfunction that brings unpredictable surgical outcomes
[1, 2]. Alleviating inflammation and thereby inhibiting
the overproduction of extracellular matrix is essential to
prevent fibrovascular proliferation and scar formation
[3, 4]. Therefore, various surgical and medical ap-
proaches have been used to reduce postoperative
inflammation and adhesion after strabismus surgery.
These include antimetabolites (5-fluorouracil, mitomy-
cin C), mechanical barriers (silicone sleeve, polyglactin
910 mesh, Seprafilm [Genzyme, Cambridge, MA, USA]),
anti-inflammatory agents (triamcinolone), and lubricants
(sodium hyaluronate) [1, 2, 5–10]. None of these, however,
has been generally accepted because of associated compli-
cations, limitations or inconsistent outcomes [4].
Tranilast is a derivative of the amino acid tryptophan
and was developed as an anti-allergy drug [11, 12]. It
also prevents inflammation and collagen synthesis
derived from keloid and hypertrophic scarring [11]. In
addition, several in vitro and in vivo studies revealed that
tranilast directly affected various parenchymal cells
as anti-inflammatory and anti-fibrotic agent. Tranilast
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significantly reduced collagen synthesis, chemotaxis, cell
migration, transforming growth factor beta 1 (TGF-β1)
secretion, matrix metalloproteinase-1 secretion, and
extracellular matrix production in various parenchymal
cells [13–18].
In the ophthalmic field, tranilast eye drops are used to
treat fibrotic ophthalmic diseases such as symblepharon,
pterygium, and corneal haze after photorefractive kera-
tectomy [19–21]. Prior study has demonstrated that dir-
ect slow-releasing tranilast could reduce adhesion and
allowed delayed adjustment after surgery [22]. However,
that is not a simple method to use in usual clinical set-
ting. And, a long-term effect and safety of direct releas-
ing system was not established in the wound healing.
Also direct exposure of tranilast could induce stromal
cell apoptosis [23].
With these backgrounds, the purpose of this study was
to evaluate the anti-fibrotic effect of tranilast eye drops
on experimental strabismus surgery in rabbit model, as
measured by gross adhesion grading and histopathologic
evaluation.
Methods
A prospective, masked observer, controlled experiment
was performed on adult female 14 New Zealand White
rabbits (DooYeol Biotech, Seoul, Korea) weighing 2.0 to
3.0 kg. which housed in alone of given 2 weeks to accli-
mate to the housing facility. The rabbits were housed in
individual mesh cages (0.90 × 0.65 × 0.50 m) hung at a
height of 0.8 cm from the collecting trays and given ac-
cess to rat maintenance food (Laboratory Rabbit Diet
5321, LabDiet, St. Louis, MO, USA) and water ad libi-
tum. Environmental conditions were a temperature of
22 °C ±2°, humidity of 50 % ±10 %, lighting of 360 lx
and a 12∶12 h light:dark cycle with lights on at 6:30 am
and off at 6:30 pm. All experiments were conducted in
accordance with the ARRIVE Guidelines for reporting
animal research. And, study protocol was approved by
Chung-Ang university institutional animal care and use
committee (number 14-0043).
Surgical procedure
We performed standard 3-mm recession with preserving
Tenon’s capsule of the superior rectus muscle (SRM)
strabismus surgery on both eyes in all rabbits. All sur-
geries were performed by the same surgeon (NJM). The
animals were anesthetized with an intramuscular injec-
tion containing a mixture of tiletamine and zolazepam
(Zoletil®, Virbac Lab, France) at 12.5 mg/kg, an aqueous
solution of 2 % xylazine (Rompun®, Bayer Korea, Seoul,
Korea) at 12.5 mg/kg, and topical anesthesia with 0.5 %
proparacaine hydrochloride eye drops (Alcaine®, Alcon,
Fort Worth, TX, USA). A 5 % povidone-iodine solution
was applied to the inferior and superior fornix before
surgery for antisepsis. The SRM was exposed through a
limbal incision and was then isolated on a muscle hook.
Three-millimeter recession was conducted with a
double-armed 7-0 polyglactin suture (Vicryl®, Ethicon,
Piscataway, NY, USA). The conjunctiva was then reposi-
tioned carefully and closed with two 7-0 polyglactin su-
tures in all eyes. Postoperatively, an antibiotic eye drop
(Cravit®, Santen, Osaka, Japan) was used three times a
day in one eye (N = 14) and an antibiotic eye drop and
0.5 % tranilast eye drops (Krix®, Choongwae Shin Yak,
Seoul, Korea) were used three times a day in the contralat-
eral eye (N = 14) which was randomly selected by using
table of random numbers. All eye drops were adminis-
tered 6:30 to 7:00, 12:30 to 13:00, and 18:30 to 19:00.
Evaluation of gross adhesions
Five weeks after the surgery all rabbits were re-
anesthetized. Then, gross adhesion grades of recession
site were evaluated. The grades were classified by
severity and were scored from 0 to 4 as follows: 0 = no
adhesion; 1 = filmy adhesion easily separable with blunt
dissection; 2 =mild-to-moderate adhesion with freely
dissectible plane; 3 =moderate-to-dense adhesion with
difficult dissection; and 4 = non-dissectible plane (Fig. 1).
Histopathological examination
After adhesion grading, the eyes were enucleated beware
of damage to the recession site. A two of 4 mm width
incision was made parallel with recession at 2 mm an-
teriorly and 4 mm posteriorly to recession site. Then in-
cision was extended to first two incisions to make
Fig. 1 Reference photograph of the degree of adhesion. a Grade 1,
filmy adhesion easily separable with blunt dissection; b grade 2,
mild-to-moderate adhesion with a freely dissectible plane; c grade 3,
moderate-to-dense adhesion with difficult dissection; d grade 4,
non-dissectible plane
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histologic block. The histologic block fixed in 10 %
formaldehyde and embedded in paraffin. Three sagittal
sections for each block were made perpendicularly to
the line of the postsurgical insertion of the SRM. Tissues
in each group were examined microscopically using
hematoxylin & eosin (H&E) staining to general histo-
logic observation. Inflammation was quantified by aver-
aging the number of inflammatory cells in three high
powered field views on light microscopy of recession site
stroma on each section. Masson’s-trichrome staining
was performed to quantification of collagen formation,
and TGF-β1 expression was identified using anti-
TGF-β1 antibody (Goat anti-Rabbit IgG Antibody;
Novusbio, Littleton, CO, USA) through immunohisto-
chemical (IHC) staining.
Quantification of fibrosis
Three sections of Masson’s-trichrome staining images
of extraocular muscle at recession site (original
magnification ×200), were obtained per each eye using
the CCD camera, light microscope, and computer software
(Zeiss AxioCam ICc1, Zeiss Axiskop40 microscope, and
ZEN 2012 software, Zeiss Korea, Seoul, Korea). Then, the
obtained images were imported into Adobe® Photoshop®
CS5 software (Adobe Systems Inc, San Jose, CA, USA).
Total pixel numbers of intermuscular collagen deposition
of each section were recorded using polygonal lasso tool
according to the previously published protocol to quantify
the degree of fibrosis [24].
Statistical analyses
Fisher’s exact test was used to determine the relationship
between the severity of adhesion (Grade 0 to 4) and the
application of tranilast eye drops. The Mann-Whitney
test was used to compare degree of inflammation on
H & E staining and amount of fibrosis on Masson’s-
trichrome staining. Statistical analyses were performed
with SPSS version 18.0 (SPSS, Inc., Chicago, IL, USA)
Table 1 Numerical gross adhesion grades for each eye
Adhesion grade 0 1 2 3 4 Total N (%)
Control 0 (0 %) 0 (0 %) 4 (29 %) 8 (57 %) 2 (14 %) 14 (100 %)
Tranilast 0 (0 %) 6 (43 %) 7 (50 %) 1 (7 %) 0 (0 %) 14 (100 %)
Fig. 2 Light microscopic findings on hematoxylin and eosin staining of group control (a, b) and group tranilast (c, d). The group control shows
more prominent fibrovascular proliferation in superior rectus muscle then the group tranilast (arrow heads in [a, b]). The group tranilast shows
scant fibrosis and inflammatory cell infiltration (c, d; left column, original magnification ×40; right column, original magnification ×100; M superior
rectus muscle, S sclera, Co Conjunctiva)
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software. The level of statistical significance was set
at 5 % (P < 0.05) for all tests.
Results
Degree of gross adhesion
Eyes in group tranilast (14/28 eyes) showed filmy adhe-
sion (score 1; 6 eyes) or mild-to-moderate adhesion
(score 2; 7 eyes) except one which had moderate-to-
dense adhesion (score 3) (Table 1). Whereas, the eyes in
group control (14/28 eyes) revealed adhesion ranging
from mild-to-moderate (score 2; 4 eyes) and moderate-
to-dense (score 3; 8 eyes) to non-dissectible (score 4; 2
eyes). There was less post-operative recession site
adhesion in group tranilast compared to group control
(P = 0.01, Fisher’s exact test). There was no adverse event
such as infection in the experimental and control
groups.
Histopathologic examination and quantitative analysis
The group tranilast demonstrated less inflammation and
fibrosis around the SRM than group control (Fig. 2).
The group control presented significantly more inflam-
matory cells (mostly small lymphocytes) than the group
tranilast (Table 2; P < 0.001, Mann-Whitney test).
Masson’s trichrome staining revealed that group control
presented more intense post-operative fibrosis than
group tranilast (Fig. 3). Moreover, in quantitative
analysis of fibrosis, there was a significant reduction of
muscle fibrosis in the tranilast treated eyes compared
with control eyes (Table 3; P < 0.001, Mann-Whitney test).
The group control showed more prominent TGF-β1
expression than group tranilast (Fig. 4).
Discussion
Several studies were performed to prevent formation of
adhesion and to alleviate motility dysfunction after stra-
bismus surgery by using various materials and medical
agents. The materials which include tissue implants such
as amniotic membrane, silicone, supramid sleeve, poly-
glactin mesh sleeves [4, 25, 26]. However, various level
of clinical success and foreign body reaction or extrusion
has discouraging the purpose of their insertion [1].
Similarly, the medical agent such as mitomycin C, and
5-fluorouracil demonstrated positive results in reducing
the postoperative adhesions and fibrosis [1, 7]. However,
these agents have the risk for serious side effects such as
corneoscleral melt [27]. More recently, monoclonal anti-
vascular endothelial growth factor antibody has been in-
vestigated to reduce postoperative adhesions. But, it was
insufficient to prevent postoperative adhesions [28].
Table 2 Inflammatory cell count per high power field on
light microscopy
Cells/HPF (mean ± SD)
Control 43.35 ± 12.25 P < 0.001*
Tranilast 23.35 ± 10.55
HPF high power field, SD standards deviation
*Mann-Whitney test
Fig. 3 Light microscopic findings from Masson’s-trichrome staining of group control (a, b, c) and group tranilast (d, e, f). The group control
shows more intense collagen deposition than group tranilast at limbal incision site (arrow heads in [a, d]). Also, there was a marked reduction in
the density of superior rectus muscle fibrosis (c, f; a, b, d, e, original magnification ×40; c, f, original magnification ×200)
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The TGF-β superfamily consists of diversiform pro-
teins that have pleiotropic function, including cell cycle
control, chemotaxis, and wound healing [29, 30]. The
TGF-β is well known as the crucial molecule in tissue
organ fibrosis [31]. The TGF-β signaling induces various
mesenchymal precursor cells to myofibroblast trans-
formation which characterized α-smooth muscle actin
expression and collagen secretion [32, 33]. TGF-β1, 2
and 3 are three isoforms exist in mammalian cells [34].
In human eye, it was previously reported that normal
conjunctiva showed much weaker expression of TGF-β
family than fibrous conjunctiva tissue [35]. Moreover,
TGF-β1 is overexpressed in cultured fibroblasts from fi-
brous conjunctiva among three isoforms of TGF-β [36].
Therefore, TGF-β, especially TGF-β1, has been the treat-
ment target to prevent the formation of postsurgical
fibrosis and adhesions in strabismus surgery [37].
To our knowledge, there are no published reports on
the histopathologic evaluation for the effect of tranilast
eye drops after strabismus surgery. This study investigated
the effects of tranilast eye drops on fibrosis and
inflammation caused by extraocular muscle surgery in
rabbits. Five weeks after operation, with 0.5 % tranilast eye
drops, the group tranilast demonstrated less gross adhe-
sion, inflammation and fibrosis than the group control.
Those findings are comparable to previous studies
reporting that a slow-release tranilast system reduced
postoperative adhesions in strabismus surgery [22].
Hwang et al. wrapped the extraocular muscle with a
sheet of polytetrafluoroethylene/polylactide-co-glycolide
laminate with tranilast, reducing adhesion during a
delayed adjustment procedure [22]. This system is highly
effective, as it directly and consistently releases the
active agent. However, a direct slow-release system re-
quires an additional complicated surgical procedure and
has the problem of remained foreign body in surgical
site with the case of standard strabismus surgery. We
therefore used more simple postoperative management
and found that tranilast eye drops were comparable to a
direct release system in terms of postoperative adhesion
and fibrosis.
Tranilast eye drops may decrease surgical site adhe-
sion and fibrosis via anti-inflammatory and anti-fibrotic
action. Tranilast eye drops showed favorable anti-
inflammatory action as a cytokine modifier. It suppress
the release of interleukin-2 and interleukin-1β from
monocytes and macrophages, which are key cytokines
that initiate inflammation [11]. Furthermore, tranilast
Table 3 Quantitative analysis of fibrosis through Masson’s
trichrome staining
Number of pixels (mean ± SD)
Control 133,798 ± 60,855 P < 0.001*
Tranilast 54,011 ± 26,873
SD standards deviation
*Mann-Whitney test
Fig. 4 Light microscopic findings of immuno-histochemical staining of anti-transforming growth factor beta 1 (TGF-β1) (a, c) and Masson’s-trichrome
staining (b, d) of the superior rectus muscle at identical sections (a, b, group control; c, d, group tranilast). Prominent TGF- β1 expression was observed
in the area of excessive collagen deposition (arrow heads in [a, b]; a, b, c, d, original magnification ×100)
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inhibits the progression of inflammation; it inhibits
chemotaxis by suppressing the expression of vascular
cell adhesion protein-1 and intercellular adhesion mol-
ecule 1 [38–40]. Additionally, tranilast has inhibitory
effect of collagen deposition by inhibiting fibroblast pro-
liferation [41] and limiting TGF-β induced fibrosis and
excessive formation of extracellular matrix inhibiting
expression of TGF-β1 [42, 43]. This effect could be
obtained even by application of eye drops and was con-
firmed using Masson’s-trichrome and IHC staining in
the present study (Figs. 3 and 4).
The present study has some limitations. Surgical out-
comes were evaluated at only one point, 5 weeks after
surgery, to ensure completion of the proliferative phase,
which includes collagen synthesis and adhesion forma-
tion [44]. This is suitable for evaluating fibrosis and sur-
gical site adhesion, but earlier postoperative evaluation
needs to clarify the role of tranilast in the acute inflam-
matory and proliferative phases of inflammation. In
addition, it is necessary to investigate the effect of other
anti-inflammatory and anti-fibrotic therapeutic agents,
such as nonsteroidal anti-inflammatory drugs and ste-
roids eye drops, compared to tranilast eye drops.
Conclusions
In conclusion, 5-week instillation of 0.5 % tranilast eye
drops is a simple and effective method for the prevention
of post-operative adhesion and fibrosis after strabismus.
This is the first experimental study to evaluate the effect
of tranilast eye drops as a treatment for postoperative ad-
hesion after strabismus surgery, through the downregula-
tion of inflammation and fibrosis.
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